Add like
Add dislike
Add to saved papers

Examination of antimicrobial activity of selected non-antibiotic drugs.

A variety of pharmaceutical preparations, which are applied in the management of non-infectious diseases, have shown in vitro some antimicrobial activity. These drugs are called "non-antibiotics". The aim of this study was to detect and characterize the antimicrobial activity of non-antibiotic drugs, selected from the preparations analysed during state control performed in the National Institute of Public Health in Poland. Over 180 of pharmaceutical preparations were randomly chosen from different groups of drugs. A surveillance study was performed on standard ATCC microbial strains used for drug control: S. aureus, E. coli, P. aeruginosa and C. albicans. It was shown that the drugs listed below inhibited growth of at least one of the examined strains: Actonel 5 mg tabl. (risedronate), Aldan 10 mg tabl. (amlodipine), Aleras 10 mg tabl. (cetirisine), Aspicam 15 mg tabl. (meloxicam), Baikadent 6 mg/g gel (flavons of Scutellariae), Debretin 100 mg tabl. (trimebutine), Ferro-Duo 100 mg tabl. (ferrum), Gastrovent 145 mg caps. (bismuth citrate), Ibum 200 mg caps., Upfen 200 mg tabl. (ibuprofen), Lastet 100 mg caps. (etoposide), Legalon 70 mg tabl. (sylimarin), Madopar 125 tabl. (benserazide, levodopa), Moxenil 100 mg tabl. (nimesulide), Neurotin 800 mg tabl. (gabapentin), Propranolol 40 mg tabl. (propranolol), Rexetin 20 mg tabl. (paroxetine), Salipax 20 mg caps. (fluoxetine), Selofen 10 mg caps. (zaleplon) Stenorol 0.6% powder (halofuginone), Stimuloton 50 mg tabl. (sertraline), Superoptim 0.3 mg tabl. (hipericine), Uversan 50 mg tabl. (arbutine from Arctostaphylos uva ursi). S. aureus strain was susceptible to the most of the drugs listed above. The lowest inhibitory concentration was found for sertraline and hipericine (0.16 and 0.075 mg/mL, respectively).

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app